Close

Anti-WT1 (RMFPNAPYL) TCR (clone D13.1), Jurkat Cell Line (TCRJ-CQ473)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The anti-WT1 (RMFPNAPYL) TCR (clone D13.1) Jurkat cell line is a stable cell line made from the anti-WT1 TCR lentivirus. The recombinant Jurkat T cell was designed to predict the MOA of WT1-TCR, measure the WT1-TCR specificity and screen target cells expressing WT1. And the product can be used to treat Cancer.

Specific Inquiry

  • Size:
  • Marker:
  • Positive rate:
  Add to Cart

Specifications

  • Cell Background
  • The Jurkat cell line was established from the peripheral blood of human T lymphocyte cells. Jurkat cells are used to study acute T cell leukemia, T cell signaling, and the expression of various chemokine receptors. Jurkat cells can produce interleukin 2, and are used in research involving the susceptibility of cancers to drugs and radiation.
  • Cell Type
  • T lymphocyte
  • Formulation
  • Containing ≥ 1 X 10*6 / vial frozen cells
  • Cell Purity
  • >95%
  • Cell Viability
  • >90%
  • Mycoplasma Testing
  • The cell line has been screened using the luciferase based mycoplasma detection kit to confirm the absence of mycoplasma species.
  • Applications
  • • Screen for activators or inhibitors of CMV signaling in a cellular context
    • Characterize the biological activity of CMV and its interactions with ligands
    • Predict the MOA of the TCR design
    • Screen and validate CMV-expressing target cells
  • Storage
  • Frozen cells should be stored in a liquid nitrogen tank (-150°C~-190°C). Once reconstituted, the cells may be used for up to five days if properly stored at 2°C - 8°C in the buffer provided.
  • Handling Notes
  • Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance.
    Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line.
    Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
  • Warnings
  • Avoid multiple freeze/thaw cycles
  • Research Use Only
  • Our recombinant Jurkat cell are for research use only, not for diagnostic or therapeutic use.
  • Quality Control
  • Cultures are screened for the presence of bacteries, yeast, fungi and mycoplasma (DNA amplification). Growth media are also certified based on U.S. Public Health Service Guidelines.
  • Tumorgenicity
  • Positive (In vitro/vivo transformation assay)
  • Oncogenicity
  • Positive (In vitro soft agarose assay and life-time studies)
  • Sterility Testing
  • Creative Biolabs provides sterility testing in accordance with USP and EP regulations. All of our sterility testing is performed in an isolator or clean room environments. The cell line has been screened using the membrane filtration testing methods to confirm the absence of aerobic, anaerobic and fungi microorganisms.
  • Identity Testing
  • Identity testing is required for newly established cell lines. Isoenzyme analysis is used to confirm the identity of the species of a cell line. Alternative methods for identity testing include DNA fingerprinting, STR analysis and karyology.
  • Virological Safety Testing
  • A broad range of viruses is susceptible to affecting human cell lines. We can provide in vivo/vitro virus saftey assays by utilizing various animal systems. These viruses include: adventitious viruses, bovine viruses, human and simian viruses, porcine viruses, retrovirus and rodent viruses.
  • Genetic Stability Testing
  • We perform cell genetic stability studies under ICH guidelines. We
    can provide guidance on the appropriate testing program upon your requirements.

TCR Design

  • Target
  • WT1
  • Introduction
  • This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
  • HLA
  • HLA-A2
  • Common Name
  • WT1
  • Target Species
  • Human
  • TCR Clone
  • D13.1
  • TCR-Host Animal
  • Human
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • Targeting Diseases
  • Cancer
  • Epitope
  • RMFPNAPYL
  • Format
  • Single-Chain TCR

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-WT1 (RMFPNAPYL) T Cell Receptor (clone D13.1), Jurkat Cell Line (TCRJ-CQ473). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.